SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (“Akero”) (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it has entered into a definitive agreement to be acquired by Novo Nordisk A/S (“Novo Nordisk”) for up to $5.2 billion in cash.
The Deal
- Novo Nordisk is paying about US$54/share in cash to acquire Akero, plus an additional US$6/share contingent on milestones. Total up to ~ US$5.2 billion.
- The key asset is Akero’s lead drug candidate, Efruxifermin, a treatment in late-stage trials for the liver disease known as metabolic dysfunction-associated steatohepatitis (MASH).
- Novo sees this as a complement to its existing portfolio (especially in obesity/diabetes) and as a way to “diversify beyond” just weight-loss/GLP-1 drugs.
- The deal is expected to close by end of 2025 (pending regulatory & shareholder approvals) according to available disclosures.
Good Strategic Fit
- High unmet need: MASH is a large and growing problem (fatty-liver disease with fibrosis / cirrhosis tied to obesity/diabetes/metabolic syndrome). Treatment options are limited. The market potential is big.
- Synergies with Novo’s strengths: Novo has major strength in metabolic diseases, obesity, diabetes. The liver disease link (especially around metabolic dysfunction) means the asset is more closely aligned than a “pure oncology” or “unrelated” buy. That helps.
- Competitive positioning: Some analysts say that Akero’s drug shows promising data (e.g., reductions in fibrosis in cirrhotic patients) which many prior assets in this space have not achieved.